Pharmaceutical global market access consultancy Valid Insight has been named as one of a select number of businesses to win the Queen’s Award for Enterprise: International Trade. The Queen’s Awards for Enterprise are the UK’s most esteemed business awards. Valid Insight, which provides expert consultancy services that guide clients in the pharmaceutical, biotech and medical device industry to global market access success, is to be honoured in recognition of its growth strategy. Since being established in 2016, the company has grown exponentially, with their international client base and sales expanding by almost 800% in the last three years. Valid Insight’s founder and Managing Director, Steve Bradshaw, who will attend a Royal Reception at Buckingham Palace in June hosted by HRH The Prince of Wales, commented: “We are honoured to receive the Queen’s Award for Enterprise in International Trade. We compete against a strong set of consultancy firms on a global level and to win this award means that what we are doing is world class”. Bradshaw added that the Queen’s Award “strengthens our reputation as a leader” and “will further encourage us to extend our high standard of expertise in the challenging area of pharmaceutical market access, helping more multinational companies bring better medicines to patients across the world”.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.